Videos

Focusing on recent approvals in earlier lines of relapsed/refractory multiple myeloma, the panel has a comprehensive discussion on the CARTITUDE-4 and KarMMa-3 studies and shares clinical insights on administering CAR T-cell therapy and monitoring patients.

A panel of experts on multiple myeloma introduce themselves and discuss recent data presented on the phase 3 IMROZ trial for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

The panelists evaluate the preliminary efficacy findings from the ECHO trial and address how the COVID-19 pandemic influenced overall survival outcomes in the study.

Key opinion leaders examine the current frontline treatment options for mantle cell lymphoma while identifying critical unmet patient needs requiring attention.

Arvind Dasari, MD, MS, outlines the evolution of colorectal cancer screening, addressing historical challenges, and the development of non-invasive screening techniques.

Leading experts offer insights into colorectal cancer, including its prevalence, staging, and the current landscape of treatment options.

A panel of oncologists in academic and community settings discuss patient monitoring practices following CAR T-cell infusions, with a focus on neurotoxicities.

Members of the panel discuss their criteria for determining when a patient is ready to transition back to community oncologists after they receive CAR T-cell therapy.

Key opinion leaders analyze recent findings from the CLEAR trial presented at ASCO 2024, focusing on the four-year follow-up data for progression-free survival and overall survival outcomes.

Key opinion leaders explore renal cell carcinoma subtypes, their incidence rates, primary sites of origin, and frequently observed genetic mutations.

Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.

Focusing on supportive care practices, the panel discusses the critical role of effective multidisciplinary team collaboration and communication in optimizing the management of CRS and ICANS in patients receiving CAR T-cell therapy.

Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.

The panel provides comprehensive insights on the treatment of ICANS following CAR T-cell therapy, highlighting the role of imaging, clinical trial data, and clinical pearls for community practices.

Experts on multiple myeloma review the study design and results from MajesTEC-1, focusing on the efficacy and safety findings, and provide insights on adverse event management practices.

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, provide an overview of the current treatment landscape in relapsed/refractory multiple myeloma.

Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.

Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.

Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.

The panel concludes the discussion by offering future perspectives on the evolving treatment landscape in multiple myeloma, highlighting exciting developments and ongoing research.

Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.

Experts on multiple myeloma provide clinical insights on how they triage and prioritize patients to best utilize available resources.

Myeloma specialists discuss their approaches to determining the optimal timing for leukapheresis for patients awaiting CAR T-cell therapy.

Donna Catamero, ANP-BC, OCN, CCRC, presents the case of a 77-year-old patient who experienced ICANS following CAR T-cell therapy and describes the role of the ICE score.

Experts on multiple myeloma provide clinical insights on strategies to manage or mitigate CRS, highlighting premedications, the role of bridging therapy, and potential treatment strategies.

Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.

Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.

Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.

Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.

Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.